Un CA à la peine mais bonne maîtrise des coûts - ACHAT - OC 91€
Le groupe français publie ce matin ses résultats du T3 2017 qui se révèlent nettement inférieurs aux attentes au niveau des ventes mais suite à un bon travail au niveau des coûts son BNA atteint 1,71€ (vs 1,72€ att). La bonne performance de la franchise Médecine de Spé (+13,9%) et Vaccins (+11%) compense la pression attendue du Diabète et de la Santé grand public. A noter que l’impact change de -5,6% au niveau des BNA vient pénaliser fortement le trimestre. La guidance du groupe est maintenue avec cependant un impact devise plus défavorable (entre -1% et - 2%). Conférence téléphonique prévue à 14h00.Sanofi is an integrated, global healthcare company focused on patient needs and engaged in the research, development, manufacture and marketing of healthcare products. Two segments make up Co.'s business: Pharmaceuticals and Vaccines. The Pharmaceuticals segment covers research, development, production and marketing of medicines, consisting of flagship products, plus a broad range of prescription medicines, generic medicines, and consumer health products. The Vaccines segment includes research, development, production and marketing of vaccines in five areas: pediatric vaccines, influenza vaccines, adult and adolescent booster vaccines, meningitis vaccines, and travel and endemic vaccines.
Since 2006, Invest Securities has become one of the leading players in investment services for funds and managers, to whom we offer a global and personalised service. Our track record differentiates us and proves our leadership in numerous promising sectors like property and growth companies.
Consisting of 13 different profiles (pharmacist, engineer, financier, etc), the DNA of our financial analysis office is value added and sector expertise. Through daily monitoring and detailed analyses of companies and sectors, we seek to provide a differentiating vision of our 120 stocks followed. Our ideas are circulated every day to nearly 1,000 professionals.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.